Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview

Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and...

Full description

Saved in:
Bibliographic Details
Published inPharmacology Research & Perspectives Vol. 9; no. 1; pp. e00705 - n/a
Main Authors Rezaee, Haleh, Pourkarim, Fariba, Pourtaghi‐Anvarian, Samira, Entezari‐Maleki, Taher, Asvadi‐Kermani, Touraj, Nouri‐Vaskeh, Masoud
Format Journal Article Web Resource
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.02.2021
John Wiley and Sons Inc
Wiley
Subjects
Acidosis
adverse reactions
Analgesics
Anemia
Animals
Antibodies, Monoclonal, Humanized - therapeutic use
Anticoagulants
Antiviral Agents - therapeutic use
Antiviral drugs
Bioavailability
chloroquine
Chloroquine - therapeutic use
Coronaviruses
COVID-19
COVID-19 - drug therapy
Dehydrogenases
Disease transmission
Drug dosages
Drug Interactions
Drug therapy
drug‐drug interaction
Enzymes
Epidemics
Fatalities
Hematology
Hepatitis
Humans
Infections
Interferon
Kaletra
Lopinavir - therapeutic use
Metabolism
Metabolites
Pancreatitis
Patients
Pharmacology
Phosphorylation
Plasma
Psoriasis
remdesivir
Review
Reviews
Ribavirin - therapeutic use
Ritonavir - therapeutic use
SARS-CoV-2
Toxicity
China
COVID-19
chloroquine
remdesivir
drug-drug interaction
adverse reactions
Kaletra
Online AccessGet full text

Cover

More Information
Summary:Drug‐drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID‐19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT‐prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID‐19 in order to minimize the adverse reactions. COVID‐19 is a life‐threatening illness with high prevalence. The use of non‐specific medications may increase the risk of drug‐drug interactions and side effects.
ISSN:2052-1707
2052-1707
DOI:10.1002/prp2.705